Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 April 2019 | Story Valentino Ndaba | Photo Valentino Ndaba
Andrew Lane
Mining the fourth industrial revolution way is the future says industry expert, Andrew Lane.

Innovation is imperative for the future of mining in South Africa. Industry expert, Andrew Lane proposes that leveraging on new information, mining technologies and energy knowhow, which are the hallmarks of the fourth industrial revolution, should set the scene for success.

Lane who is Africa Energy and Resource Leader at Deloitte, engaged students at a recent guest lecture hosted by the University of the Free State’s Business School on the Bloemfontein Campus. “The future is intelligent mining. It’s not just about technology; it’s about changing the way you do business,” he said.

Transforming traditional to trailblazing
“What gives you sustainable competitive advantage is the rate at which you innovate,” said Lane. Design paradigm shifts in the South African mining industry may have resulted in about 100 000 job losses during the past four years. However, mining companies stand to achieve significant gains through applying innovation.

Despite most of South Africa’s mines nearing the end of their lives, mining remains a large employer and investor attractor which ensures that the country holds a competitive advantage in the global economy. Lane is adamant that, “even though we have declined from 20% to 5% in terms of GDP contributions, mining remains a large contributor to export earnings”.

Reaching resource-rich regions
While some physical resources are inaccessible using current technology, “new mineral-processing technologies help tap into previously uneconomical mineral deposits”, according to Lane. In addition to the environment, 3D visualisation cameras can track employees and equipment in the bowels of the earth.

More mining, less loss
Integrating mining, energy, and information technology will ensure that companies reduce people, capital and energy intensity, while increasing mining intensity. The impossible can be achieved if technology is used well for developmental outcomes, employment, and improving standards of living.



News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept